Pfizer Return on Investment 2012-2026 | PFE
Current and historical return on investment (ROI) values for Pfizer (PFE) over the last 10 years.
| Pfizer ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2026-03-31 | $14.54B | $74.26B | 19.58% |
| 2025-12-31 | $14.24B | $111.32B | 12.80% |
| 2025-09-30 | $13.72B | $147.80B | 9.28% |
| 2025-06-30 | $14.83B | $147.81B | 10.03% |
| 2025-03-31 | $12.05B | $147.56B | 8.16% |
| 2024-12-31 | $12.41B | $148.95B | 8.33% |
| 2024-09-30 | $5.78B | $150.18B | 3.85% |
| 2024-06-30 | $-2.35B | $152.11B | -1.55% |
| 2024-03-31 | $-1.16B | $155.90B | -0.75% |
| 2023-12-31 | $1.28B | $150.67B | 0.85% |
| 2023-09-30 | $10.79B | $145.16B | 7.44% |
| 2023-06-30 | $22.91B | $136.98B | 16.72% |
| 2023-03-31 | $32.93B | $127.26B | 25.88% |
| 2022-12-31 | $35.79B | $123.61B | 28.95% |
| 2022-09-30 | $33.55B | $119.82B | 28.00% |
| 2022-06-30 | $30.76B | $116.50B | 26.40% |
| 2022-03-31 | $24.15B | $112.47B | 21.47% |
| 2021-12-31 | $19.43B | $108.94B | 17.84% |
| 2021-09-30 | $17.15B | $105.68B | 16.22% |
| 2021-06-30 | $13.45B | $106.44B | 12.63% |
| 2021-03-31 | $9.91B | $108.80B | 9.11% |
| 2020-12-31 | $8.25B | $108.15B | 7.63% |
| 2020-09-30 | $2.62B | $107.85B | 2.43% |
| 2020-06-30 | $3.13B | $104.39B | 3.00% |
| 2020-03-31 | $5.32B | $99.64B | 5.34% |
| 2019-12-31 | $6.71B | $97.96B | 6.85% |
| 2019-09-30 | $5.62B | $97.27B | 5.78% |
| 2019-06-30 | $6.43B | $98.24B | 6.54% |
| 2019-03-31 | $6.14B | $98.98B | 6.20% |
| 2018-12-31 | $5.67B | $100.85B | 5.62% |
| 2018-09-30 | $14.00B | $102.99B | 13.59% |
| 2018-06-30 | $13.90B | $100.56B | 13.82% |
| 2018-03-31 | $13.66B | $99.02B | 13.80% |
| 2017-12-31 | $13.72B | $97.19B | 14.12% |
| 2017-09-30 | $13.17B | $93.70B | 14.06% |
| 2017-06-30 | $12.53B | $93.31B | 13.43% |
| 2017-03-31 | $12.26B | $93.47B | 13.12% |
| 2016-12-31 | $12.15B | $92.49B | 13.13% |
| 2016-09-30 | $12.22B | $93.12B | 13.13% |
| 2016-06-30 | $12.56B | $93.66B | 13.41% |
| 2016-03-31 | $12.68B | $93.76B | 13.52% |
| 2015-12-31 | $11.82B | $95.20B | 12.42% |
| 2015-09-30 | $12.14B | $97.56B | 12.44% |
| 2015-06-30 | $12.46B | $101.00B | 12.34% |
| 2015-03-31 | $12.82B | $104.83B | 12.23% |
| 2014-12-31 | $13.25B | $107.02B | 12.38% |
| 2014-09-30 | $14.15B | $108.00B | 13.10% |
| 2014-06-30 | $14.45B | $108.05B | 13.37% |
| 2014-03-31 | $14.78B | $108.37B | 13.64% |
| 2013-12-31 | $15.18B | $110.52B | 13.74% |
| 2013-09-30 | $14.70B | $111.92B | 13.13% |
| 2013-06-30 | $14.46B | $112.68B | 12.83% |
| 2013-03-31 | $15.04B | $112.76B | 13.34% |
| 2012-12-31 | $15.26B | $113.49B | 13.45% |
| 2012-09-30 | $14.62B | $114.70B | 12.74% |
| 2012-06-30 | $14.96B | $117.88B | 12.69% |
| 2012-03-31 | $14.12B | $121.35B | 11.63% |
| 2011-12-31 | $13.97B | $123.50B | 11.31% |
| 2011-09-30 | $13.94B | $125.78B | 11.08% |
| 2011-06-30 | $13.62B | $126.07B | 10.80% |
| 2011-03-31 | $13.80B | $126.06B | 10.94% |
| 2010-12-31 | $13.41B | $126.69B | 10.59% |
| 2010-09-30 | $11.49B | $128.43B | 8.94% |
| 2010-06-30 | $11.85B | $121.32B | 9.77% |
| 2010-03-31 | $10.77B | $113.94B | 9.46% |
| 2009-12-31 | $10.96B | $102.22B | 10.72% |
| 2009-09-30 | $13.43B | $85.24B | 15.76% |
| 2009-06-30 | $12.75B | $79.20B | 16.09% |
| 2009-03-31 | $12.25B | $73.88B | 16.58% |
| 2008-12-31 | $11.73B | $72.39B | 16.20% |
| 2008-09-30 | $11.65B | $74.05B | 15.73% |
| 2008-06-30 | $8.58B | $73.59B | 11.66% |
| 2008-03-31 | $7.09B | $73.60B | 9.64% |
| 2007-12-31 | $7.52B | $74.03B | 10.16% |
| 2007-09-30 | $6.93B | $75.17B | 9.21% |
| 2007-06-30 | $10.17B | $75.83B | 13.41% |
| 2007-03-31 | $11.76B | $75.84B | 15.51% |
| 2006-12-31 | $12.12B | $75.56B | 16.05% |
| 2006-09-30 | $13.03B | $74.36B | 17.52% |
| 2006-06-30 | $11.27B | $73.60B | 15.32% |
| 2006-03-31 | $11.26B | $72.82B | 15.47% |
| 2005-12-31 | $11.20B | $72.29B | 15.49% |
| 2005-09-30 | $12.08B | $73.15B | 16.52% |
| 2005-06-30 | $14.46B | $74.18B | 19.49% |
| 2005-03-31 | $15.07B | $74.83B | 20.14% |
| 2004-12-31 | $14.21B | $75.39B | 18.84% |
| 2004-09-30 | $12.68B | $74.28B | 17.07% |
| 2004-06-30 | $10.82B | $73.94B | 14.63% |
| 2004-03-31 | $3.94B | $74.82B | 5.27% |
| 2003-12-31 | $4.26B | $62.91B | 6.76% |
| 2003-09-30 | $5.56B | $50.90B | 10.92% |
| 2003-06-30 | $6.14B | $37.68B | 16.30% |
| 2003-03-31 | $12.02B | $23.91B | 50.27% |
| 2002-12-31 | $11.59B | $22.33B | 51.91% |
| 2002-09-30 | $10.45B | $21.78B | 47.97% |
| 2002-06-30 | $10.24B | $21.51B | 47.62% |
| 2002-03-31 | $10.32B | $21.08B | 48.95% |
| 2001-12-31 | $9.89B | $20.43B | 48.41% |
| 2001-09-30 | $7.92B | $19.50B | 40.59% |
| 2001-06-30 | $6.92B | $18.61B | 37.20% |
| 2001-03-31 | $5.99B | $17.63B | 33.97% |
| 2000-12-31 | $3.74B | $15.40B | 24.27% |
| 2000-09-30 | $4.82B | $13.45B | 35.86% |
| 2000-06-30 | $3.42B | $11.42B | 29.96% |
| 2000-03-31 | $3.02B | $9.65B | 31.32% |
| 1999-12-31 | $3.89B | $9.37B | 41.49% |
| 1999-09-30 | $3.90B | $9.35B | 41.67% |
| 1999-06-30 | $4.52B | $9.32B | 48.57% |
| 1999-03-31 | $3.91B | $9.28B | 42.11% |
| 1998-12-31 | $3.41B | $9.11B | 37.36% |
| 1998-09-30 | $2.41B | $8.95B | 26.90% |
| 1998-06-30 | $1.87B | $8.69B | 21.48% |
| 1998-03-31 | $1.69B | $8.41B | 20.08% |
| 1997-12-31 | $1.58B | $8.15B | 19.41% |
| 1997-09-30 | $1.79B | $7.89B | 22.70% |
| 1997-06-30 | $2.18B | $7.64B | 28.58% |
| 1997-03-31 | $2.54B | $7.30B | 34.81% |
| 1996-12-31 | $2.80B | $6.95B | 40.35% |
| 1996-09-30 | $2.83B | $6.63B | 42.67% |
| 1996-06-30 | $2.68B | $6.26B | 42.90% |
| 1996-03-31 | $2.50B | $5.97B | 41.91% |
| 1995-12-31 | $2.30B | $5.68B | 40.46% |
| 1995-09-30 | $2.25B | $5.33B | 42.30% |
| 1995-06-30 | $2.07B | $5.10B | 40.56% |
| 1995-03-31 | $2.01B | $4.82B | 41.71% |
| 1994-12-31 | $1.97B | $4.60B | 42.90% |
| 1994-09-30 | $1.88B | $4.48B | 41.91% |
| 1994-06-30 | $1.82B | $4.39B | 41.39% |
| 1994-03-31 | $1.74B | $4.51B | 38.68% |
| 1993-12-31 | $1.67B | $4.66B | 35.73% |
| 1993-09-30 | $1.62B | $4.87B | 33.16% |
| 1993-06-30 | $1.57B | $5.29B | 29.70% |
| 1993-03-31 | $1.52B | $5.50B | 27.68% |
| 1992-12-31 | $1.44B | $5.65B | 25.53% |
| 1992-09-30 | $1.35B | $5.69B | 23.69% |
| 1992-06-30 | $1.32B | $5.48B | 24.05% |
| 1992-03-31 | $1.29B | $5.32B | 24.26% |
| 1991-12-31 | $1.25B | $5.25B | 23.91% |
| 1991-09-30 | $1.20B | $5.21B | 23.10% |
| 1991-06-30 | $1.16B | $5.21B | 22.28% |
| 1991-03-31 | $1.12B | $5.18B | 21.67% |
| 1990-12-31 | $1.05B | $5.07B | 20.79% |
| 1990-09-30 | $1.02B | $4.93B | 20.59% |
| 1990-06-30 | $0.98B | $4.81B | 20.38% |
| 1990-03-31 | $0.95B | $4.73B | 20.09% |
| 1989-12-31 | $0.97B | $4.67B | 20.72% |
| 1989-09-30 | $0.97B | $4.62B | 20.92% |
| 1989-06-30 | $0.97B | $4.56B | 21.30% |
| 1989-03-31 | $1.05B | $4.52B | 23.27% |
| 1988-12-31 | $1.01B | $4.44B | 22.79% |
| 1988-09-30 | $1.01B | $4.34B | 23.20% |
| 1988-06-30 | $0.99B | $4.22B | 23.46% |
| 1988-03-31 | $0.99B | $4.11B | 24.06% |
| 1987-12-31 | $0.94B | $3.98B | 23.60% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |